You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 25, 2024

Litigation Details for In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

✉ Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in In Re: Purdue Pharma L.P.
The small molecule drug covered by the patent cited in this case is ⤷  Sign Up .

Details for In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

Date Filed Document No. Description Snippet Link To Document
2021-11-15 158 ATTN: GENERAL COUNSEL U.S. PAT. NO. 7,658,945 DATED MARCH …relating to its patents for OxyContin and related efforts to preserve patent exclusivity; … Address 2. 2214 ASSIGNMENT OF CANADIAN PATENT 100027 … ABBOTT PARK, IL 60064-3500 2. 2220 PATENT LICENSE AGREEMENT AMONG … CHICAGO, IL 2. 2227 PATENT LICENSE AGREEMENT AMONG External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.